Will Compass record a goodwill impairment charge related to the Anywhere acquisition by June 30, 2027?

The earnings update is modestly favorable for the NO case. Synergies at $175M actioned in 6.5 weeks (target raised to $250M Year 1) and FY2025 standalone EBITDA of $293M provide strong operational evidence that the combined entity is performing. This supports the cash flow projections that underpin goodwill fair value in impairment testing. However, the stock at $10.12 creates a tension: market cap of ~$7.3B versus merger enterprise value of ~$10B implies the market is skeptical about value creation. If market cap stays materially below goodwill carrying value (which won't be known until PPA is finalized, likely H2 2026), it becomes a potential triggering event for interim impairment testing. The key question is timing: even if impairment risk exists, will it manifest within the 18-month window (by June 2027)? Companies typically resist impairment charges aggressively, and the first annual test is likely Q4 2026 or Q1 2027. Management will use optimistic projections to defend against impairment.

The impairment analysis requires separating two questions: (1) is the goodwill economically impaired? and (2) will the company record an accounting impairment by June 2027? On question 1, the stock price suggests possible economic impairment — the market values the combined entity below the deal price. But stock price alone doesn't trigger accounting impairment; it's one of many factors. On question 2, the path to recording an impairment requires: PPA finalization (12-18 months, so H2 2026 - H1 2027), then either an annual test or a triggering event. The annual test is typically set at a convenient date (often Q4). Even if the test occurs in Q4 2026, management has significant latitude in setting discount rates, growth assumptions, and terminal values. With $293M standalone EBITDA growing, $175M+ synergies, and aggressive projections, management can construct a defensible fair value above carrying amount. The only path to impairment by June 2027 is a severe housing downturn or integration failure that makes optimistic projections indefensible.

I want to weight the bear case more carefully. The stock at $10.12 versus the convertible note conversion price of $15.98 is a significant signal — it means the converts are deeply out of the money, suggesting the equity market doesn't believe the combined entity will achieve the value implied by the deal. If the stock remains below $10 through 2026 and EBITDA doesn't reach the $700M+ combined level, the gap between market valuation and carrying value widens. Auditors will push for impairment testing if the gap persists. The 43x synergy premium was aggressive at signing — if Year 1 synergies land at $200-250M (as guided) but the market still values the company below deal price, it creates auditor pressure. Additionally, if Q1 2026 combined EBITDA is weak (due to seasonality), the stock could decline further, creating a triggering event. I'll weight this slightly higher than my co-panelists at 14% to account for the persistent market cap deficit.

Base rate for goodwill impairment within 18 months of a large acquisition: approximately 10-15%. This base rate already accounts for the general tendency of acquirers to overpay and for integration challenges. The COMP-specific factors cut both ways: synergy execution is ahead of plan (reducing risk) but the stock price suggests market skepticism (increasing risk). The earnings update doesn't dramatically change the calculus — it provides one positive data point (synergies) while the structural factors (PPA timeline, management resistance, 18-month window) remain unchanged. I'll anchor near the base rate at 10%.

The initial estimate of 13% reflected appropriate skepticism about the 18-month window being too short for impairment. The earnings update provides modest positive evidence: EBITDA growth ($126M → $293M YoY), synergy acceleration, and no integration red flags. However, the stock price has not recovered to levels consistent with the deal valuation, which slightly offsets the operational positives. Net effect: modest downward revision from 13% to 11%. The probability is primarily driven by the base rate for large acquisitions and the inherent difficulty of management recording impairment within 18 months.

The resolution date is September 30, 2027, covering filings through Q2 2027 10-Q. The first annual impairment test is likely Q4 2026 (standard timing). If the test occurs in Q4 2026 and reveals impairment, it would be recorded in the Q4 2026 10-K (filed ~March 2027), which is within the window. Alternatively, an interim triggering event in early 2027 could force testing. The probability tree: P(annual test in Q4 2026) = 70%, P(impairment found | test) = 10-15%, P(interim trigger + impairment in H1 2027) = 3-5%. Combined: ~10-15%. The positive earnings data reduces the P(impairment found | test) slightly, bringing us to ~12%.

Synergies ahead of plan ($175M actioned). EBITDA growing strongly ($293M FY2025). Integration progressing. These all support NO impairment. Stock below deal price is concerning but companies don't impair based on stock price alone. 18-month window is tight. Management will fight to avoid impairment. Base rate of 10-15% applies, leaning toward lower end given positive execution.

Stock at $10.12 vs. $15.98 conversion price means converts are out of the money, but the impairment test uses DCF methodology, not market cap. Management will use optimistic long-term projections. Synergy acceleration supports higher projected cash flows. PPA isn't even finalized — goodwill amount is unknown. Hard to impair what hasn't been quantified yet. Q4 2026 annual test is the first real risk point, but management will set it up to pass.

Previous estimate of 13% was reasonable. Earnings update is modestly positive: synergies ahead of plan, strong standalone EBITDA. But stock price below deal value is a yellow flag. Net effect: slight downward revision to 12%. The base rate for large, leveraged acquisitions is the main driver. First annual test in Q4 2026 is the key event — if it passes, the probability drops to near zero for the remaining window.